Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Donnelly, R.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Review: Managing cardiovascular risk in patients with diabetes

Richard Donnelly

The Medical School, Derby City General Hospital, Uttoxeter Road, Derby, DE22 3DT, UK, richard.donnelly{at}nottingham.ac.uk

The increasingly large number of patients with diabetes in the UK are at greatly increased risk of cardiovascular disease, including coronary heart disease and stroke, compared to the general population. Many diabetes patients exhibit metabolic syndrome and these additional risk factors, such as raised hypertension and cholesterol, multiply the overall risk. Reducing these risk factors to target levels is essential and requires a multifactorial approach. Lifestyle changes, tight glycaemic control, antiplatelet drugs (aspirin) and control of lipid levels, e.g. using statins, can all have significant beneficial effects. Blood pressure control is another vital aspect in reducing risk and a number of recent studies have provided evidence supporting the use of angiotensin-converting enzyme inhibitors as first-line treatment in patients with diabetes.

Key Words: ACE inhibitor • cardiovascular disease • diabetes • hypertension • metabolic syndrome.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 325-329 (2005)
DOI: 10.1177/14746514050050060501
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?